Important Therapy Provides Six Months Pain Relief with Single Injection CAMBRIDGE, Mass.--(BUSINESS WIRE)--Genzyme Corporation (Nasdaq: GENZ) today announced that the U.S. Food and Drug Administration ...
Genzyme Corporation today announced that the FDA's Orthopaedic and Rehabilitation Devices Advisory Committee voted unanimously (5 - 0) in favor of approval without conditions of Synvisc-One TM (hylan ...
CAMBRIDGE, Mass., Nov. 13 /PRNewswire-FirstCall/ -- Genzyme Corp. announced today that it has received a letter from the U.S. Food and Drug Administration requesting ...
Feb. 6, 2003 (New Orleans) — In a head-to-head study comparing intra-articular hylan GF-20 injection (Synvisc) to corticosteroid injection for knee osteoarthritis, "there was no difference in outcome ...
To earn CME related to this news article, click here. March 5, 2009 — The US Food and Drug Administration (FDA) has approved budesonide plus formoterol fumarate dihydrate inhalation aerosol for the ...
Co announces that it has received a letter from the FDA requesting additional analyses and data regarding the marketing application for Synvisc-One in the United States. The co now expects that ...
CAMBRIDGE, Mass. Genzyme, a biotech company has announced that the Food and Drug Administration has delayed the release of the company’s new osteoarthritis drug, Synvisc-One because, the agency wants ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback